tpcgif Texas Pulmonary & Critical Care Consultants, P.A.

 

Forms
 

 

 

Authorized Access Only

FWSW/Hug Group
N Arl Group
NE Group

 
Dr. John Burk - Presentations, Publications, and Clinical Trials

Presentations:

  1. “A Treatment Success Index for Positive Airway Pressure Therapy of Obstructive Sleep Apnea”, Associated Professional Sleep Societies, San Antonio, Texas, June 9, 2010.

  2. “Lack of Major Interspousal Sleep Disruption Between Spouses Who Both Have Intrinsic Sleep Disorders”, Associated Professional Sleep Societies, San Antonio, Texas, June 7, 2010.

  3. “Do Spouses With Intrinsic Sleep Disorders Disturb Each Other’s Sleep?”, New Orleans, Louisiana, May 19, 2010. 

  4. "Obstructive Sleep Apnea in the Perioperative Patient", American Society of PeriAnesthesia Nurses 27th National Conference, Grapevine, Texas, May 6, 2008.

  5. "New Options for the Treatment of Restless Legs Syndrome (RLS)", Boehringer Ingelheim Pharmaceuticals, Inc., Del Frisco’s, Fort Worth, Texas, February 27, 2007.

  6. "Treatment of Moderate to Severe Primary Restless Legs Syndrome", Fort Worth Clinic, Fort Worth, Texas, February 26, 2007.

  7. "Methemoglobinemia - A Quality Report", Baylor Southwest Fort Worth, Baylor All Saints and Texas Society for Respiratory Care, Quality Initiatives for 2006, State National Bank, Fort Worth, Texas, June 30, 2006.

  8. "OSA in the Perioperative Patient", National Respiratory Care Week Seminar, Baylor All Saints Medical Center, Fort Worth, Texas, October 27, 2005.

  9. "Initiation and Termination of Ventilator Support", Harris Methodist Fort Worth Hospital and North Texas Specialty Physicians, October 8, 2005.

  10. "COPD: An Approach to Primary Care Management", Texas Academy of Family Physicians, July 8, 2004.

  11. "Sleep Apnea and its impact on the patient with heart disease," The American Heart Association, Osteopathic Medical Center & Plaza Medical Center of Fort Worth: Southwest Regional Cardiovascular Review 2003, Fort Worth, Texas, April 23, 2003."Cardiovascular Sequelae of Obstructive Sleep Apnea," Greater Fort Worth Society of Gastroenterology Nurses and Associates, Fort Worth, Texas, March 8, 2003.

  12. "Smallpox & the Respiratory Care Practitioner," Spring Respiratory Care Seminar, Fort Worth, Texas, April 5, 2002.

  13. "Interventional Bronchoscopy," Spring Respiratory Care Seminar, Fort Worth, Texas, April 5, 2002.

  14. "Interventional Bronchoscopy," Texas Society for Respiratory Care Annual Convention & Exhibition, San Anontio, Texas, July 17-19, 2002.

  15. "Interventional Bronchoscopy," Greater Fort Worth Society of Gastroenterology Nurses and Associates, 13th Annual Educational Symposium: A GI Odyssey, Fort Worth, Texas, February 24, 2001.

  16. "Auto-CPAP in the Treatment of Obstructive Sleep Apnea," Mid West Association of Polysomnographic Technologists, Rosemont, Illinois, November 10, 1995.

  17. "Auto-CPAP in the Treatment of CPAP-Using Obstructive Sleep Apnea Patients," International Scientific Assembly of the American College of Chest Physicians, 61st Annual Meeting, New York, New York, October 29-November 2, 1995.

  18. "Indications and Considerations for Auto-CPAP Therapy," Association of Polysomnographic Technologists, Nashville, Tennessee, June 1995.

  19. "Auto-CPAP (APAP) in the Treatment of Obstructive Sleep Apnea," European Respiratory Society, Nice, France, October 1994.

  20. "Auto-CPAP in the Initial Treatment of Obstructive Sleep Apnea (OSA) Patients," Association of Professional Sleep Societies, Seventh Annual Meeting, Los Angeles, California, June 1993.

  21. "Auto-CPAP in the Initial Treatment of Obstructive Sleep Apnea (OSA) Patients," Advances in Sleep Medicine, Winter Meeting, February 1993.

  22. "Auto-CPAP in the Treatment of Obstructive Sleep Apnea: A New Approach," Association of Professional Sleep Societies, Phoenix, Arizona, June 1992.

  23. "Auto-CPAP in the Treatment of Obstructive Sleep Apnea: A New Approach," Advances in Sleep Medicine, Winter Meeting, February 1992.

  24. "Who Should Have Sleep Studies?" Texas Medical Association Annual Meeting, May 1989.

  25. "Epidemiology of Nursery Exposure to Tuberculosis," American College of Chest Physicians, November 1977.

  26. "Consecutive Cases of Fiberoptic Transbronchial Pulmonary Biopsy," KOPPA Conference, Hunt, Texas, August 1976; presented with R. L. Ragsdale and J. Robertson.

  27. "Hypertension Control: Where Do We Stand Now in Alabama?" CIBA Symposium, Birmingham, Alabama, November 1975.

Publications:

  1. Al-Abed Mohammad A; Manry Michael; Burk John R; Lucas Edgar A; Behbehani Khosrow, “Sleep disordered breathing detection using heart rate variability and R-peak envelope spectrogram,” Proceedings of The 31st Annual International Conference of the IEEE-EMBS, 2009.

  2. E. Estrada, H. Nazeran, P. Nava, K. Behbehani, J.R. Burk, and E. A. Lucas, "Itakura Distance: A Useful Similarity Measure Between EEG and EOG Signals in Computer-aided Classification of Sleep Stages," Proceedings of The 27th Annual International Conference of the IEEE-EMBS, 2005.

  3. Balakrishnan G, Behbehani K, Lucas EA, Burk JR: An Investigation of Bispectral Index for Detection of Sleep-Disordered Breathing. Sleep, Volume 28, Abstract Supplement, 2005, page A207.

  4. G. Balakrishnan, K. Behbehani, D. Bruli, J.R. Burk, and E. A. Lucas, "Comparison of a Sleep Quality Index between Normal and Obstructive Sleep Apnea Patients," Proceedings of The 27th Annual International Conference of the IEEE-EMBS, 2005.

  5. S. R. Suhas, K. Behbehani, S. Vijendra, J.R. Burk, and E. A. Lucas, "Spectral Analysis of R Wave Attenuation and Heart Rate Variability for Detection of Cheyne Stokes Breathing," Proceedings of The 27th Annual International Conference of the IEEE-EMBS, 2005.

  6. S. R. Suhas, K. Behbehani, S. Vijendra, J.R. Burk, and E. A. Lucas, "Time Domain Analysis of R-Wave Attenuation Envelope for Sleep Apnea Detection," Proceedings of The 26th Annual International Conference of the IEEE-EMBS, pp 3885-3888, 2004.

  7. S. Vijendra, K. Behbehani, E. A. Lucas, J.R. Burk, D. N. Burli, and D. H. Dao "The Use of R-wave morphology in the Detection of Sleep-Disordered Breathing using the Electrocardiogram –– A Comparison between Leads," Proceedings of The 26th Annual International Conference of the IEEE-EMBS, pp 3881-3884, 2004.

  8. F Estrada, H. Nazeran, P. Nava, K Behbehani, J.R. Burk, and E.A. Lucas, "EEG Signal Feature Extraction for Classification of Sleep Staging," Proceedings of The 26th Annual International Conference of the IEEE-EMBS, pp 196-199, 2004.

  9. Burk, John R: Automatic CPAP: The Next Generation. RT Magazine, June/July 1999, pages 37-42.

  10. Lucas EA, Behbehani K, Bradshaw CM, Burk JR, Knaur S, Wexler DM: Comparison of Continuous Positive Airway Pressure (CPAP) to AutoCPAP* (APAP) in the Diagnosis and Treatment of Obstructive Sleep Apnea. Sleep, Volume 21, Number 3, Supplement, 1998, page 106.

  11. Yen FC, Behbehani K, Lucas EA, Burk JR, Axe JR: A Noninvasive Technique for Detecting Obstructive and Central Sleep Apnea. IEEE Transactions on Biomedical Engineering, Volume 44, Number 12, December 1997, pp 1262-1268.

  12. Behbehani KR, Becker PM, Burk JR, Jamieson AO, Jewell CE, Knaur SL, Lucas EA, Shehadeh F and Smith ML: ABSTRACT: Hours of Use Is Increased and Mean Therapeutic Pressure Is Reduced by Auto CPAP (APAP) Therapy in CPAP Treated Obstructive Sleep Apnea Patients. Sleep Research, Volume 26, page 326, Chase MH, Rosenthal LD, O'Connor C, eds. 1997.

  13. Smith ML, Becker PM, Behbehani K, Burk JR, Jamieson AO, Jewell CE, Knaur SL, Lucas EA and Shehadeh F: ABSTRACT: Comparison of Auto CPAP (APAP) and Fixed CPAP Therapy on Nocturnal Blood Pressure Changes in Patients with Obstructive Sleep Apnea. Sleep Research, Volume 26, page 511, Chase MH, Rosenthal LD, O'Connor C, eds. 1997.

  14. Behbehani KR, Lopez F, Yen F-C, Lucas EA, Burk JR, Axe JP, Kamangar F: Pharyngeal Wall Vibration Detection Using an Artifical Neural Network. Medical & Biological Engineering & Computing, Volume 35, May 1997, pp 193-198.

  15. Behbehani KR, Yen F-C, Burk JR, Lucas EA, Axe JR: Automatic Control of Airway Pressure for Treatment of Obstructive Sleep Apnea. IEEE Transactions on Biomedical Engineering, Volume 42, Number 10, October 1995, pp 1007-1016.

  16. Creticos P, Burk JR, Smith L, Comp R, Norman P, Findlay S: The Use of Twice Daily Nedocromil Sodium in the Treatment of Asthma. Journal of Clinical Immunology, April 1995.

  17. Burk JR: Community Ethics Conference Report. Tarrant County Physician, Volume 66, Number 4, April 1994, p 35.

  18. Burk JR: Camp El Tesoro de la Vida. Tarrant County Physician, Volume 62, Number 6, June 1990, p 33.

  19. Wooten V, Lucas EA, Burk JR: Positive Nasal Airway Pressure Eliminates Snoring As Well As Obstructive Sleep Apnea. Pulmonary Disease Review, Volume 6, 1986, pp 575-583.

  20. Burk JR, Viroslav J, Bynum LJ: Miliary Tuberculosis Diagnosed by Fiberoptic Bronchoscopy and Transbronchial Biopsy. Tubercle, Volume 59, 1978, pp 107-109.

  21. Burk JR, Bahar D, Wolf FS, Greene J, Bailey WC: Nursery Exposure of 528 Newborns to Nurse with Tuberculosis. The Southern Medical Journal, Volume 71, Number 1, January 1978, pp 7-10.

  22. Burk JR, Lertora JJL, Maetinex IM, Fisher JW: Renal Cell Carcinoma with Erythrocytosis and Elevated Erythropoietic Stimulatory Activity. The Southern Medical Journal, Volume 70, Number 8, August 1977.

  23. Burk JR: Hypertension Control: Where Do We Stand Now in Alabama? The Journal of the Medical Association of the State of Alabama, Volume 45, Number 9, March 1976, pp 26-28.

  24. Burk JR, Snow R, Sellers C, Hicks A, Maetz M, Atkins R, Lindsey HS: St. Louis Encephalitis in Jefferson County-1974: What Does the Future Hold? The Journal of the Medical Association of the State of Alabama, Volume 44, Number 12, June 1975, pp 693-697.

  25. Burk JR, Lehman HF, Wolf FS: Inadequacy of Papanicolaou Smears in the Detection of Endometrial Cancer. The New England Journal of Medicine, Volume 291, Number 4, July 25, 1974, pp 191, 192.

Clinical Trials:

  1. “A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in patients with moderate to severe chronic obstructive pulmonary disease, using salmeterol as an active control.” [Novartis Pharmaceuticals Corporation], March, 2010, ongoing. Principal Investigator.

  2. “A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.” [Novartis Pharmaceuticals Corporation], February, 2010, ongoing. Sub-Investigator. 

  3. “A twelve-week treatment, multi-center, randomized double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease.” [Novartis Pharmaceuticals Corporation], January, 2010, ongoing. Principal Investigator. 

  4. “A long-term, randomized, double-blind, extension study of the safety, tolerability, and efficacy of aclidinium bromide at two dosage levels when administered to patients with moderate to severe chronic obstructive pulmonary disease.” [Forest Research Institute], October, 2009, ongoing. Principal Investigator. 

  5. “Efficacy and safety of aclidinium bromide at three dose levels (200μg twice daily, and 400μg twice daily, and 200μg once daily) vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).” [Forest Research Institute]. April, 2009, ongoing. Principal Investigator. 

  6. “Efficacy and safety of aclidinium bromide at two dose levels (200μg twice daily, 400μg twice daily), versus placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).” [Forest Research Institute], March, 2009. Principal Investigator.

  7. "A twelve (12) week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of Indacaterol (150 ug. o.d.) via a SDDPI in patients with moderate to severe COPD, using salmeterol (50 ug. b.i.d.) as an active comparator delivered via a DISKUS inhaler." [Novartis Pharmaceuticals Corporation], February, 2009, ongoing. Principal Investigator.

  8. "A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 mcg and 5 mcg) administered once daily via the Respimat® devise for 12 weeks in patients with cystic fibrosis". [Boehringer Ingelheim], November, 2008, ongoing. Principal Investigator.

  9. "A randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and Fluticasone Propionate inhalation powder (500 ug) twice daily compared with placebo for eight weeks in adolescent and adult subjects with persistent asthma symptomatic on moderate dose of ICS therapy." [GlaxoSmithKline], March, 2008, ongoing. Principal Investigator.

  10. "A randomized double-blind, double-dummy, placebo-controlled, parallel group, multicenter dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and Fluticasone Propionate inhalation powder (250 ug) twice daily compared with placebo for eight weeks in adolescent and adult subjects with persistent asthma symptomatic on low dose ICS therapy." [GlaxoSmithKline], March, 2008, ongoing. Principal Investigator.

  11. "A randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center dose ranging study to evaluate the efficacy and safety of GW685698X inhalation powder once daily and Fluticasone Propionate inhalation powder (100ug) twice daily compared with placebo for eight weeks in adolescent and adult subjects with persistent asthma symptomatic on non-steroidal asthma therapy." [GlaxoSmithKline], March, 2008, ongoing. Principal Investigator.

  12. "A 12-week treatment, multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of Indacaterol (150 ug once a day) in patients with chronic obstructive pulmonary disease." [Novartis Pharmaceuticals Corporation], January, 2008. Principal Investigator.

  13. "A 26-week extension to a 26-week treatment, multi-center, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel group study to assess safety, tolerability, and efficacy of two doses of Indacaterol (150 and 300 ug once a day) in patients with chronic obstructive pulmonary disease." [Novartis Pharmaceuticals Corporation], February, 2008. Principal Investigator.

  14. "A randomized, double-blind, placebo-controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200 ug once a day) in patients with moderate to severe chronic obstructive pulmonary disease." [Novartis Pharmaceuticals Corporation], March, 2007. Principal Investigator.

  15. "A 26-week treatment, multi-center, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel group study to assess the efficacy, safety, and tolerability of two doses of Indacaterol (selected from 75, 150, 300, and 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded Formoterol (12 ug b.i.d.) And open-label tiotropium (18 ug o.d.) as active controls." [Novartis Pharmaceuticals Corporation], May, 2007. Principal Investigator.

  16. "A randomized, double-blind, placebo-controlled, parallel group, stratified, multi-center, 12-week study comparing the safety and efficacy of Fluticasone and Formoterol combination (FlutiForm 100/10ug or 250/10ug twice daily) in a single inhaler (SkyePharma HFA pMDI) with the administration of placebo or Fluticasone (250ug twice daily) and Formoterol (10ug twice daily) alone in adolescent and adult patients with moderate to severe asthma." [SkyePharma AG], October, 2006. Principal Investigator.

  17. "A 52-week randomized, double-blind, parallel group, placebo controlled, multicenter clinical trial, to assess the efficacy and safety of 200ug of the anticholinergic LAS 34273 compared to placebo, both administered once daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease." [Almirall Prodesfarma, S.A.], June 2006. Principal Investigator.

  18. "A 12-Month, Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of SYMBICORT pMDI 2 x 160 / 4.5 mcg b.i.d. and 2 x 80 / 4.5 mcg b.i.d. Compared to Formoterol TBH 2 x 4.5 mcg b.i.d. and Placebo in Patients with C.O.P.D." [Astra-Zeneca], May 2006. Principal Investigator.

  19. "Effect of roflumilast on exacerbation rate in patients with c.o.p.d. A 52-weeks, double-blind study with 500 mcg roflumilast once daily versus placebo." [Altana Pharma], May 2006. Principal Investigator.

  20. "A Randomized, 24-Week, Double-Blind, Placebo Controlled, Parallel group Study to Evaluate the Efficacy, Safety and Tolerability of Ariflo (15 mg b.i.d.) in Patients with Chronic Obstructive Pulmonary Disease." Study CIL103657, November 2004. Principal Investigator.

  21. "An Epidemiologic Study of Xolair (Omalizumab: Evaluating Clinical Effectiveness and Long Term Safety in Patients with Moderate to Severe Asthma" (Excels). Study Q2948g Genetech, Inc., June 2004. Principal Investigator (ongoing trial)

  22. "A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50 mcg B.I.D. with Salmeterol Diskus 50 mcg B.I.D. on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease." Study SCO40043, GlaxoSmithKline Inc, September 2004. Principal Investigator.

  23. "A Multi-Center, Randomized, Double-Blind, Double-Dummy, Parallel Group, 8 Week Comparison of Salmeterol Xinafoate Versus Salmeterol Xinafoate plus Ipratropium Bromide Versus Placebo in Subjects With Chronic Obstructive Pulmonary Disease". Study SMS 40314 Glaxo Wellcome, Inc., June 2000. Principal Investigator.

  24. "A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Trial Evaluating the Safety and Efficacy of the Diskus Formulations of Salmeterol 50mcg B.I.D. and Fluticasone Propionate 250mcg B.I.D. Individually and in Combination as Compared to Placebo in Chronic Obstructive Pulmonary Disease Subjects". Study SFCA 3007, Glaxo Wellcome, Inc., 1999. Sub-Investigator.

  25. "Comparative Study of APAP and CPAP Performance for Treatment of Obstructive Sleep Apnea at Home." 1996-1997. Principal Investigator.

  26. "Auto-CPAP With and Without a Humidifier." Study 1CA5052, Respironics, Inc., April 1995 to December 1996. Principal Investigator.

  27. "A Multicenter Study for the Correlation Between the Findings of Atypical/Malignant Cells in Sputum and Fluorescent Bronchoscopy Using the LIFE Imaging System and White Light Bronchoscopy." Protocol LS01, Xillix Technologies Corporation, June 1994. Principal Investigator.

  28. "A Multicenter, Prospective Survey to Evaluate Purulent Lower Respiratory Tract Exacerbations in the Outpatient Setting." Study Z0556n, Genentech, Incorporated, July 1995, Co-Investigator.

  29. "Real-Time Non-Invasive Method for Estimating Upper Airway Impedance of Apnea Patient During Sleep." December 1994 to December 1996. Principal Investigator.

  30. "A Multinational, Multicenter, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized Recombinant Human DNase I in Hospitalized Patients with Chronic Obstructive Pulmonary Disease Experiencing a Pulmonary Exacerbation." August 1994 to September 1995. Principal Investigator.

  31. "Enhanced CPAP Therapy for Obstructive Sleep Apnea." Study 1 R15 HL46467-01A1, National Institutes of Health and the University of Texas at Arlington, September 1992 to August 31, 1994, Co-Investigator.

  32. "A Microprocessor-Controlled Continuous Positive Airway Pressure System for Treating Obstructive Respiratory Impairments in Sleep." January 1992 to September 1995, Co-Investigator.

  33. "Prospective, Controlled, Third Party-Blind, Randomized Study Comparing the Efficacy and Safety of IV/PO Ciprofloxacin (400/500 mg q.12h.) with Parenteral IV or IM Ceftriaxone (1000 mg q.24h.) in the Treatment of Patients with Pneumonia (Multi-Center)." Study D89-027, Miles, Inc., Pharmaceutical Division, November 1990. Principal Investigator.

  34. "Prospective, Controlled, Randomized Study Comparing the Efficacy and Safety of Intravenous Ciprofloxacin with Standard Antibiotic Therapy in the Treatment of Selected Tissue Infections (Multi-Center)." Study D90-034, Miles, Inc., Pharmaceutical Division, November 1990, Co-Investigator.

  35. "The Effect of Zolpidem in Elderly Patients with Chronic Insomnia." Study LSH-21, Lorex Pharmaceuticals, January 1990. Principal Investigator.

  36. "Cefaclor A.F. vs. Cefaclor in Various Bacterial Infections." Study B3M-M-AIKA, Eli Lilly & Company, January 1989, Co-Investigator.

  37. "Development of a Microprocessor-Based Sleep Apnea Ventilator." Project #1805, Texas Higher Education Coordination Board and the University of Texas at Arlington, June 1, 1988 to August 31, 1991, Co-Investigator.

  38. "A Comparison of the Efficacy and Tolerance of Ventolin in Solution for Inhalation to Alupent Inhalant Solution to Placebo in Home Nebulization in Adults with Chronic Obstructive Pulmonary Disease." [Glaxo Pharmaceuticals], April 1988. Principal Investigator.

  39. "A Comparative Study of the Long Term Safety Profile of Estazolam, Triazolam, and placebo in Adults with Insomnia." Abbott Laboratories, 1987-1988, Co-Investigator.

  40. "A Double-Blind Multicenter Group Comparative Study of the Efficacy and Safety of Tilade b.i.d. (Nedocromil Sodium) vs. Placebo in the Management of Adults with Reversible Airway Obstruction." Study 87-11A, Fisons, November 1987. Principal Investigator.

  41. "A Comparative Patient Preference Study of Two Actuators for Ventolin Inhalers." Study SAL-508-3, Glaxo Pharmaceuticals, June 1987. Principal Investigator.

  42. "Compassionate Use of Ciprofloxacin in the Treatment of a Patient With an Infection Refractory to Currently Marketed Antibiotics." Study U86-006-96, Miles Laboratories, August 1986, Co-Investigator.

  43. "A Comparative Study of the Side Effect Profile of Estazolam, Flurazepam, Temazepam, Triazolam, and Placebo in Adult Patients Complaining of Insomnia." Protocol M84-051, Abbott Laboratories, 1986, Co-investigator.
Back To Dr. John Burk C.V. | Back To Doctors | Back Home

Material Copyright © 2001 Texas Pulmonary Consultants